Related Experiment Video

Updated: Jan 1, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.4K

Efficacy of JAK inhibitors in Ulcerative Colitis

Marc Ferrante1, João Sabino1

  • 1Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.

Journal of Crohn'S & Colitis
|December 28, 2019
PubMed

Insights

Janus kinase (JAK) inhibitors offer a new treatment for immune disorders. Tofacitinib effectively induces and maintains remission in ulcerative colitis patients, including those previously treated with anti-tumour necrosis factor therapies.

Area of Science:

  • Immunology
  • Gastroenterology
  • Pharmacology

Background:

  • Janus kinase (JAK) inhibitors represent a novel therapeutic class for immune-mediated inflammatory disorders.
  • Tofacitinib, an oral JAK inhibitor, is now approved for moderate-to-severe ulcerative colitis.
  • Ulcerative colitis is a chronic inflammatory bowel disease requiring effective treatment options.

Purpose of the Study:

  • To review the efficacy of Janus kinase (JAK) inhibitors in treating ulcerative colitis.
  • To consolidate data on various JAK inhibitors explored for ulcerative colitis treatment.
  • To provide an overview of current evidence for JAK inhibitors in managing ulcerative colitis.

Main Methods:

  • Systematic review of published clinical trial data.
  • Analysis of efficacy outcomes from placebo-controlled studies, including the OCTAVE programme.
  • Inclusion of data from both anti-tumour necrosis factor-naïve and exposed patient populations.

Main Results:

  • Tofacitinib demonstrated efficacy in inducing and maintaining clinical remission in ulcerative colitis.
  • Efficacy was observed in patients regardless of prior anti-tumour necrosis factor exposure.
  • Several other Janus kinase (JAK) inhibitors are under investigation for ulcerative colitis.

Conclusions:

  • Janus kinase (JAK) inhibitors are a promising new treatment modality for ulcerative colitis.
  • Tofacitinib offers a viable oral treatment option for patients with moderate-to-severe ulcerative colitis.
  • Further research into various anti-JAK inhibitors will expand treatment options for ulcerative colitis.
Keywords:
JAK inhibitionefficacytofacitinibulcerative colitisupadacitinib

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.2K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.7K

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
389
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.6K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
403
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
419
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
399
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
372